By Professor Sallie Pearson

Conference Papers

Stavrou EP; Lu CY; Pearson S-A, 2011, 'The Role of Comorbidity in the Uptake of Chemotherapy and Cancer Survival', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. S279 - S280, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294946600618&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pearson S; Srasuebkul P; Harris C; Ward RL; Dobbins TA; Harris C, 2010, 'Trastuzumab treatment outcomes according to concomitant chemotheray regimen: Overall survival of HER2+ metastatic breast cancer patients', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S187 - S187, presented at Pharmacoepidemiology & Therapeutic Risk Management, Brighton, UK, 19 August 2010 - 22 August 2010, http://dx.doi.org/10.1002/pds

Pearson S; Chin M; Ward RL, 2009, 'The Financially Tolerable Dose: A New Concept in Cancer Trial Design', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S173 - S174

Pearson S; Ringland C; Ward RL, 2008, 'Off-label trastuzumab use in Australia: Evidence from the national Herceptin Program for HER-2 positive metastatic breast cancer', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. 66 - 66, presented at Pharmacoepidemiology and Drug Safety

Ringland C; Pearson S; Ward RL, 2008, 'Survival of women treated with trastuzumab for HER-2-positive metastatic breast cancer: Estimating outcomes in clinical practice using administrative data', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. 436 - 437, presented at Pharmacoepidemiology and Drug Safety

Back to profile page